类风湿性关节炎患者在使用甲状腺素的前三个月经历的与药物相关的问题:一项纵向观察性研究
M A M Oude Lansink1,2,3, S A S Pongers4, C L Bekker5
1Department of Research, Sint Maartenskliniek, Hengstdal 3, 6574 NA, Ubbergen, Nijmegen, The Netherlands. m.oudelansink@maartenskliniek.nl.
International journal of clinical pharmacy
|April 3, 2025
概括
类风湿性关节炎患者在开始服用甲状腺素 (MTX) 后的三个月内报告了许多与药物相关的问题 (DRPs). 早期解决这些问题可以改善治疗的坚持和持续性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
- 患者护理 患者护理
背景情况:
- 甲托雷克萨特 (MTX) 是一种主要治疗类风湿性关节炎 (RA) 的药物.
- 与药物相关的问题 (DRP) 经常发生在MTX,影响患者的坚持和治疗持续性.
- 了解早期的DRP对于优化RA管理至关重要.
研究的目的:
- 量化RA患者在MTX治疗的前三个月中DRP的发生率和类型.
- 为了确定与早期MTX使用相关的常见患者报告的DRP.
主要方法:
- 进行了一项纵向观察性研究,其中成人RA患者开始MTX.
- 患者采访是在启动后的2,6周和12周进行的,使用标准化指南.
- 使用患者报告的DRP系统对DRP进行分类,并进行描述性分析.
主要成果:
- 所有50名参与者都经历了至少一个DRP,平均每位患者6个DRP.
- 最常见的DRP包括对副作用,恶心,疲劳以及药物坚持/理解的担忧.
- 在第2周和第6周发现的大量DRP (33%) 在第12周仍未解决.
结论:
- 在RA患者在MTX治疗过程的早期遇到大量的DRP.
- 迅速解决DRP对于减少治疗负担和提高患者的坚持和持续性至关重要.
- 早期干预策略是必要的,以有效地管理DRPs在RA患者在MTX.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
98
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
98
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Phase II Reactions: Methylation Reactions
72
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
72
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
84
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
84
Drugs for Treatment of Ulcerative Colitis in IBD
101
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
101
Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79


